Document is current
Any future updates will be listed below
-
Authors
Isaksson, Karolin
Katsarelias, Dimitrios
Mikiver, Rasmus
Carneiro, Ana
Ny, Lars
Olofsson Bagge, Roger
-
Funding
Funding for this research was provided by:
Translational Grant from Region Skåne & Lund University
M. Paulsson Fund
Knut och Alice Wallenbergs Foundation
S. Paulsson Fund
Kamprad Foundation
Swedish state (ALF-grant number 826061)
Gunnar Nilssons Foundation
Craaford Foundation
Swedish state (ALF-grant number 76670)
- License Information
-
More Information
Article History
Received: 1 February 2019
First Online: 20 May 2019
Disclosures
: ROB has received research grants from Astra Zeneca, speaker honorarium from Roche and Pfizer, and has served on advisory boards for Amgen, BMS, and MSD (the advisory boards for BMS and MSD has concerned adjuvant treatment of melanoma). LN has received honoraria for speakers from AstraZeneca, BMS, and MSD, served on Advisory Boards for BMS, MSD, Novartis, and Pierre Fabre, and received Research Grants from Merck/MSD (Inst) and Syndax Pharmaceuticals (Inst). The other authors have no conflicts of interest to declare.
